Cheplapharm Arzneimittel
{{Short description|German pharmaceutical company}}
{{Infobox company
| name = Cheplapharm
| logo = Cheplapharm Arzneimittel logo.svg
| type = Gesellschaft mit beschränkter Haftung (GmbH)
| industry = Pharmaceutical
| location = Mesekenhagen, Germany
| key_people = {{Plainlist|
- Sebastian F. Braun {{small|(CEO)}}
- Bianca Y. Juha {{small|(CSO)}}
- Edeltraud Lafer {{small|(COO)}}
- Jens Rothstein {{small|(CFO){{Cite web|url=https://www.cheplapharm.com/1/impressum/|title=Imprint|website=cheplapharm.com|language=en|access-date=2018-10-11}}}}}}
| area_served = Worldwide
| products = prescription medications
over-the-counter drugs and other medical products
| revenue = Euro 223 million
| revenue_year = 2017
| parent = Braun Beteiligungs GmbH{{Cite web|url=http://www.braun-beteiligungen.de/1/shareholdings/pharmaceutical-sector/ |title=Shareholdings – Pharmaceutical sector|website=braun-beteiligungen.de|language=en|access-date=2018-10-11}}
| num_employees_year = July 2021
| homepage = [https://www.cheplapharm.com/ www.cheplapharm.com]
}}
File:2159 Bild Nr.116, 13x20.jpg
Cheplapharm Arzneimittel GmbH, headquartered in Greifswald, is a German pharmaceutical company that markets branded drugs, medical products, supplements and cosmetics.
Cheplapharm is among the most notable small and medium-sized enterprises (SME) in the federal state of Mecklenburg-Western Pomerania,{{Cite web|url=http://www.ostsee-zeitung.de/Vorpommern/Greifswald/Pharmafirma-investiert-210-Millionen-Euro|title=Pharmafirma investiert 210 Millionen Euro|trans-title=Pharmaceutical company to invest 210 Mio. Euro|website=ostsee-zeitung.de|language=de|date=2017-09-01|access-date=2018-10-11|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013062443/http://www.ostsee-zeitung.de/Vorpommern/Greifswald/Pharmafirma-investiert-210-Millionen-Euro|url-status=dead}}{{Cite web|url=https://www.apotheke-adhoc.de/nachrichten/detail/politik/mecklenburg-vorpommern-merkel-bei-cheplapharm-millionen-investment-angekuendigt/|author=Lothar Klein|title=Merkel bei Cheplapharm|trans-title=Merkel visits Cheplapharm|website=apotheke-adhoc.de|language=de|date=2017-09-01|access-date=2018-10-11}} and part of Braun Beteiligungs GmbH, a family owned business conglomerate that is among that state's 25 biggest employers.{{Cite web|url=https://www.lfi-mv.de/export/sites/lfi/publikationen/analysen-der-NORD_LB-zur-Wirtschaft-in-M-V/download-publikationen-der-nord-lb/Mecklenburg-Vorpommern-Report-Dez.-2017-Die-100-groessten-Unternehmen.pdf|title=Die 100 größten Unternehmen in Mecklenburg-Vorpommern|trans-title=The 100 largest companies in Mecklenburg-Vorpommern|website=lfi-mv.de|language=de|date=2017-12-01|access-date=2018-10-11|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013053947/https://www.lfi-mv.de/export/sites/lfi/publikationen/analysen-der-NORD_LB-zur-Wirtschaft-in-M-V/download-publikationen-der-nord-lb/Mecklenburg-Vorpommern-Report-Dez.-2017-Die-100-groessten-Unternehmen.pdf|url-status=dead}}{{Cite web|url=http://www.ostsee-zeitung.de/Nachrichten/Wirtschaft/Die-Erfolgs-Familie|author=Cornelia Meerkatz|title=Die Erfolgs-Familie. Mit Medizin, Mode und Wurst macht die Greifswalder Braun-Gruppe Hunderte Millionen Euro Umsatz|trans-title=A successful family. Greifswald-located Braun Group's revenues from pharma, fashion and sausage reach hundreds of millions of euros|website=ostsee-zeitung.de|language=de|date=2016-11-25|access-date=2018-10-11|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013055438/http://www.ostsee-zeitung.de/Nachrichten/Wirtschaft/Die-Erfolgs-Familie|url-status=dead}} Subsidiaries of the company are located in Hamburg, Levallois-Perret (France) and Englewood, New Jersey.
Cheplapharm acts as a divestment partner for various large pharmaceutical companies.{{Cite web|url=https://www.cheplapharm.com/fileadmin/Ablage/Downloads/CHEPLAPHARM_Divestment/CHEPLAPHARM_Divestment_032018.pdf|title=Business development|website=cheplapharm.com|language=en|access-date=2018-10-11|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013055438/https://www.cheplapharm.com/fileadmin/Ablage/Downloads/CHEPLAPHARM_Divestment/CHEPLAPHARM_Divestment_032018.pdf|url-status=dead}}{{Cite web|url=http://www.sueddeutsche.de/wirtschaft/daniel-sachs-ich-bin-ein-schattenbanker-1.3653714|title=Ich bin ein Schattenbanker|trans-title=I am a shadow banker|website=sueddeutsche.de|language=de|date=2017-09-06|access-date=2018-10-11}}{{Cite web|url=https://scrip.pharmaintelligence.informa.com/deals/201020607|title=AZ grants clomethiazole rights to Cheplapharm
|website=scrip.pharmaintelligence.informa.com|language=en|date=2016-08-01|access-date=2018-10-11}}{{Cite web|url=https://scrip.pharmaintelligence.informa.com/deals/201220610|title=Cheplapharm gets rights to two drugs from Roche|website=scrip.pharmaintelligence.informa.com|language=en|date=2016-08-01|access-date=2018-10-11}} Since its foundation in 1998, Cheplapharm has acquired exclusive rights for more than 80 drugs and other pharmaceutical products that their developers intended to divest for economic or strategic reasons, generating yearly double-digit growth rates with this international “buy and build“ strategy. As of 2018, the company holds more than 400 pharmaceutical product registrations in over 120 countries worldwide.{{Cite web|url=http://www.cheplapharm.com/fileadmin/Ablage/Downloads/CHEPLAPHARM_Factsheet/EN/CP-Factsheet-EN_032018.pdf|title=Factsheet|website=cheplapharm.com|language=en|access-date=2018-10-11|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013053952/http://www.cheplapharm.com/fileadmin/Ablage/Downloads/CHEPLAPHARM_Factsheet/EN/CP-Factsheet-EN_032018.pdf|url-status=dead}}
History
The company was founded 1998 in Freiburg by Kurt Teubner, who had been working as a manager for Ciba Geigy (now Novartis). The name Cheplapharm derives from the plant based diuretic Cheplaren,{{cite journal |last1=Barschneider |first1=M.|date=February 1959|title=[Cheplaren, a plant extract diuretic]|journal=Dtsch Med J. |volume=10|issue=3|pages=63–67|language=German|pmid=13639739}} one of the first products Teubner acquired.{{Cite web|url=https://www.apotheke-adhoc.de/nachrichten/detail/markt/cheplapharm-riemser-reloaded-apotheke-pharma-braun-greifswald/|author=Patrick Holstein|title=Riemser reloaded|website=apotheke-adhoc.de|language=de|date=2015-02-04|access-date=2018-10-12}}
In 2003, Cheplapharm was bought by the Braun family. The new proprietors moved operations to Mesekenhagen, where Norbert and Dagmar Braun owned another pharmaceutical company, Riemser AG, a spin-off of the Friedrich Loeffler Institute.{{Cite web|url=https://www.bvkap.de/beteiligungskapital/finanzierungsbeispiele/riemser-arzneimittel-ag-auf-expansionskurs-mit|author=Patrick Holstein|title=Riemser Arzneimittel AG: Auf Expansionskurs mit spezialisiertem Beteiligungskapital
|trans-title=Riemser Pharma AG: On a course of expansion with specialized equity capital|website=bvkap.de|language=de|access-date=2018-10-12}} Their son Sebastian F. Braun assumed the CEO position at Cheplapharm.
Over the years, Cheplapharm has acquired the rights to more than 80{{Cite web|url=https://www.cheplapharm.com/produkte/produkte-von-a-z/|title=Produkte von A bis Z|trans-title=Our products from A to Z|website=cheplapharm.com|language=de|access-date=2018-10-12}} branded pharmaceuticals and medical products from multinational and German pharmaceutical companies. Among them are large corporations like Merck, F. Hoffmann-La Roche, AstraZeneca, Sanofi, Boehringer Ingelheim and Johnson & Johnson as well as midsize businesses like Grünenthal, Klosterfrau or Riemser. Key acquisitions were those of Heminevrin/Distraneurin (a sedative used to treat acute alcohol withdrawal), from AstraZeneca, in 2010, Rohypnol (a hypnotic) and Vesanoid (a leukemia medication, both from F. Hoffmann-La Roche, in 2012), Deursil/Ursolvan (an anti-gallstone medication, from Sanofi in 2014), Dilatrend (a beta blocker), Xenical (an anti-obesity medication) and Anexate (a benzodiazepine antagonist, all three from F. Hoffmann-La Roche in 2016),{{Cite web|url=https://www.cheplapharm.com/1/news/detail/news/largest-private-sector-investment-in-mecklenburg-western-pomerania-cheplapharm-makes-the-megadeal/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=2170d555c656ca5b5d644fa391f9c0ad|title=Largest private sector investment in Mecklenburg-Western Pomerania: CHEPLAPHARM makes the megadeal|website=cheplapharm.com|language=en|date=2016-10-27|access-date=2018-10-12|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013055443/https://www.cheplapharm.com/1/news/detail/news/largest-private-sector-investment-in-mecklenburg-western-pomerania-cheplapharm-makes-the-megadeal/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=2170d555c656ca5b5d644fa391f9c0ad|url-status=dead}}{{Cite web|url=https://www.cheplapharm.com/1/news/detail/news/cheplapharm-acquires-product-rights-for-anexater-from-f-hofmann-la-roche/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=fb0faa5eea0945f4d8f4345278317009|title=Cheplapharm acquires product rights for Anexate® from F. Hofmann-La Roche|website=cheplapharm.com|language=en|date=2016-01-20|access-date=2018-10-12|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013053837/https://www.cheplapharm.com/1/news/detail/news/cheplapharm-acquires-product-rights-for-anexater-from-f-hofmann-la-roche/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=fb0faa5eea0945f4d8f4345278317009|url-status=dead}}{{Cite web|url=http://www.ostsee-zeitung.de/Vorpommern/Usedom/Cheplapharm-hat-bei-den-Grossen-eingekauft|title=Cheplapharm hat bei den Großen eingekauft|trans-title=Cheplapharm has shopped the big name companies|website=ostsee-zeitung.de|language=de|date=2016-01-09|access-date=2018-10-12|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013062446/http://www.ostsee-zeitung.de/Vorpommern/Usedom/Cheplapharm-hat-bei-den-Grossen-eingekauft|url-status=dead}} Konakion and Cymevene (a vitamin K supplement and a virostatic, from F. Hoffmann-La Roche in 2018),{{Cite web|url=https://www.cheplapharm.com/1/news/detail/news/cheplapharm-continues-its-expansion-course-and-complements-its-portfolio-with-four-further-products/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=fdbbf75b461404f086ebfcb2cb3c6529|title=Cheplapharm continues its expansion course and complements its portfolio with four further products|website=cheplapharm.com|language=en|date=2018-01-26|access-date=2018-10-12|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013055441/https://www.cheplapharm.com/1/news/detail/news/cheplapharm-continues-its-expansion-course-and-complements-its-portfolio-with-four-further-products/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=fdbbf75b461404f086ebfcb2cb3c6529|url-status=dead}} Visudyne (a photosensitizer used for photodynamic therapy of the wet form of macular degeneration, from Novartis in 2018) and Sotacor/Sotalex (an antiarrhythmic, from Bristol-Myers Squibb in 2018).{{Cite web|url=http://www.cheplapharm.com/1/news/detail/news/cheplapharm-further-enhances-its-portfolio-in-the-cardiology-area/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=d53bfee374d3e4711e322dd087e2e055|title=Cheplapharm further enhances its portfolio in the Cardiology area|website=cheplapharm.com|language=en|date=2018-08-05|access-date=2018-10-12|archive-date=2018-10-13|archive-url=https://web.archive.org/web/20181013055435/http://www.cheplapharm.com/1/news/detail/news/cheplapharm-further-enhances-its-portfolio-in-the-cardiology-area/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=d53bfee374d3e4711e322dd087e2e055|url-status=dead}}
In 2017, Cheplapharm signed a distributorship agreement with an Orexigen Therapeutics subsidiary to market Mysimba, a combination drug for weight loss, in Germany, France and Austria.{{Cite web|url=https://www.prnewswire.com/news-releases/orexigen-therapeutics-announces-commercialization-and-distributorship-arrangement-with-cheplapharm-arzneimittel-gmbh-for-mysimba-in-germany-france-and-austria-300500226.html|title=Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria|website=prnewswire.com|language=en|date=2018-08-07|access-date=2018-10-12}} Cheplapharm also markets several over-the-counter remedies of local renown or niche appeal in Germany. Among them are Reisegold (an antiemetic with Dimenhydrinate, marketed specifically for motion sickness), the valerian extract-based sedative Baldrian Dispert, and a number of herbal tinctures from the 'Thüringer' brand formerly owned by Klosterfrau.
Cheplapharm has expanded its operations by taking over the pharma companies Walter Ritter GmbH & Co., Hamburg (2008), Sanavita Pharmaceuticals, Werne (2012) and Glenwood LCC, New Jersey{{Cite web|url=http://www.glenwood-llc.com/|title=Glenwood, LCC|access-date=2018-10-12|archive-date=2018-10-01|archive-url=https://web.archive.org/web/20181001142314/http://www.glenwood-llc.com/|url-status=dead}} (2014). The latter company's main product is Potaba, an urological drug. The French subsidiary Cheplapharm France SAS, located in Levallois-Perret, was established in 2016.{{Cite web|url=https://www.societe.com/societe/cheplapharm-france-821144979.html|title=Cheplapharm France|website=societe.com|access-date=2018-10-12}}
In 2017, Cheplapharm founded a joint venture with the German medical technology company Clearum. The venture, by the name of Med-Tec Holding GmbH, is meant to focus on manufacture of medical technology products, research and development.{{Cite web|url=http://www.globallegalchronicle.com/clearum-gmbh-and-cheplapharm-arzneimittel-gmbh-estabilishes-med-tec-holding-gmbh/|author=Paolo Bossi|title=Clearum GmbH and Cheplapharm Arzneimittel GmbH {{as written|estab|ilishes [sic]}} Med-Tec Holding GmbH
|website=globallegalchronicle.com|language=en|date=2017-10-28|access-date=2018-10-12}}{{Cite web|url=https://www.aerzteblatt.de/nachrichten/83021/Pharma-und-Medizintechnikfirma-gruenden-neues-Unternehmen|title=Pharma- und Medizintechnikfirma gründen neues Unternehmen|trans-title= Pharma und medical technology companies found new enterprise|website=aerzteblatt.de|language=de|date=2017-10-20|access-date=2018-10-12}}{{Cite web|url=https://www.nnn.de/lokales/rostock/mit-medizintechnik-auf-den-weltmarkt-id18126476.html|title=Mit Medizintechnik auf den Weltmarkt|trans-title=Medical technology for the global market|website=nnn.de|language=de|date=2017-10-21|access-date=2018-10-12}}{{Cite web|url=https://www.welt.de/regionales/mecklenburg-vorpommern/article169840408/Pharma-und-Medizintechnikfirma-gruenden-neues-Unternehmen.html|title=Pharma- und Medizintechnikfirma gründen neues Unternehmen|trans-title=Pharma und medical technology companies found new enterprise|website=welt.de|language=de|date=2017-10-20|access-date=2018-10-12}} Construction of a new production facility near Rostock has been announced to start in July 2018.{{Cite web|url=http://www.ostsee-zeitung.de/Mecklenburg/Guestrow/Dialyse-Filter-fuer-China-In-Laage-entsteht-neues-Werk|title=Dialyse-Filter für China: In Laage entsteht neues Werk|trans-title= Dialysis filters for China: New plant to be built in Laage|website=ostsee-zeitung.de|language=de|date=2018-05-24|access-date=2018-10-12}}
In 2020, the company invested in product portfolios from Takeda and Leo Pharma.{{Cite web |title=LEO Pharma sells four non-core products to Cheplapharm |url=https://www.thepharmaletter.com/article/leo-pharma-sells-four-products-to-cheplapharm |access-date=2022-08-19 |website=www.thepharmaletter.com}} The Takeda portfolio, which comprises 17 products, was the company's largest acquisition to date in terms of scope and purchase price (EUR 450 million).{{Cite web |date=2021-01-25 |title=Detail{{!}}Cheplapharm Greifswald |url=https://www.cheplapharm.com/news/detail/bisher-groesste-akquisition-fuer-cheplapharm/ |access-date=2022-08-19 |archive-date=2021-01-25 |archive-url=https://web.archive.org/web/20210125070013/https://www.cheplapharm.com/news/detail/bisher-groesste-akquisition-fuer-cheplapharm/ |url-status=bot: unknown }}{{Cite web |date=2020-09-14 |title=Cheplapharm kauft mit Latham Wirkstoffe von Takeda und Leo Pharma |url=https://www.juve.de/deals/fuer-mehr-umsatz-cheplapharm-kauft-mit-latham-wirkstoffe-von-takeda-und-leo-pharma/ |access-date=2022-08-19 |website=juve.de |language=de-DE}} In 2021, all rights to the epilepsy drug Rivotril were acquired from Roche, and Astellas took over the approvals for four branded antibiotics and De Nol,{{Cite web |title=Greifswald: Cheplapharm sichert sich Rechte an Epilepsie-Medikament Rivotril |url=https://www.ostsee-zeitung.de/lokales/vorpommern-greifswald/greifswald/greifswald-cheplapharm-sichert-sich-rechte-an-epilepsie-medikament-UA7HJIK4S3DEHPG2UO7I377GSA.html |access-date=2022-08-19 |website=www.ostsee-zeitung.de |language=de}} a drug against Helicobacter pylori infections, for Russia, Ukraine and other CIS countries.{{Cite web |title=Astellas divest legacy products to Cheplapharm; drops vaccine candidat |url=https://www.thepharmaletter.com/article/astellas-divest-legacy-products-to-cheplapharm-drops-vaccine-candidate |access-date=2022-08-19 |website=www.thepharmaletter.com}}
Products
Cheplapharm owns global or local marketing and distribution rights for a number of prescription drugs that are used in cardiology (Dilatrend, Aldactone, Inhibace, Sotalex/Sotacor, Pertenso, Dopegyt, Natrilix, Vascal), haematooncology (Vesanoid), urology (Potaba), gastroenterology and bariatrics (Deursil/Ursolvan, Cotazym, Xenical, Mysimba), emergency medicine (Anexate), addiction medicine (Heminevrin/Distraneurin), sleep medicine (Rohypnol, Aponal), infection control (Cymevene, Lariam) and ophthalmology (Visudyne).
The company also markets over-the-counter drugs for common health issues (e.g. antiemetics, antacids, antidiarrhoeals, cardiovascular remedies, painkillers, sedatives) and medical products, among them dietary supplements, hot-cold-packs, cold sprays and dermatological care products.